Equillium’s pipeline consists of the following novel first-in-class immunomodulatory assets.

Itolizumab: A monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells. Data from a Phase 3 study in first-line acute graft-versus-host disease (aGVHD) and a Phase 2 in Ulcerative colitis were announced in the first quarter of 2025, and a Phase 1b clinical study of patients with lupus/lupus nephritis was announced in April 2024.

EQ101: a tri-specific cytokine inhibitor targeting IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. Data from a Phase 2 proof-of-concept clinical study of patients with alopecia areata was reported in June 2024.

EQ302: an selective bi-specific cytokine inhibitor targeting IL-15 and IL-21, two cytokines central to T and B cell activity that exhibit biological synergy driving aggressive inflammatory responses in a number of gastrointestinal and skin diseases.